Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma · 2025-10 · Volume 12 · 2341-2349
DOI: 10.2147/jhc.s548785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-10. Verfasst von Ching-Tso Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background and Aims: Early alpha-fetoprotein (AFP) response has been reported to predict the treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC). We evaluated the predictive value of another HCC tumor marker, protein induced by vitamin K absence/antagonists-II (PIVKA-II).
Methods
We prospectively established a cohort of advanced HCC patients who received ICI treatment at two medical centers. Serum PIVKA-II levels were obtained before and within 4 weeks after treatment initiation. Any decline in serum PIVKA-II levels was defined as an early PIVKA-II response. Treatment response, overall survival (OS), and progression-free survival (PFS) were compared between patients with and without an early PIVKA-II response.
Results
In total, 67 patients were included; liver reserve was Child-Pugh class A in all patients and albumin-bilirubin grade 1 in 67.2% of the patients. An early PIVKA-II response, which was observed in 19 (28.4%) patients, was associated with a higher objective response rate (50.0% vs 16.4%, p = 0.002). Patients with an early PIVKA-II response had superior OS (median 34.3 vs 13.7 months, p = 0.015) and PFS (median 8.4 vs 4.0 months, p = 0.049) compared with those without a response. In multivariate analysis, an early PIVKA-II response remained an independent predictor for longer OS (p = 0.012) and PFS (p = 0.044). An early PIVKA-II response can complement an early AFP response in predicting prognosis.
Conclusion
An early PIVKA-II response is predictive of tumor response and superior survival outcomes in patients who received ICIs for advanced HCC. PIVKA-II is an emerging tumor marker for HCC, widely used in diagnosis and prognostic stratification. Early PIVKA-II response, defined as any decline of serum PIVKA-II level within 4 weeks after initiation of ICIs treatment, may predict treatment efficacy for patients with advanced HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
ORCID-Profile: Ching-Tso Chen, Chien-Huai Chuang, Yu-Yun Shao
Zitieren
APA
Chen, C. T., Chuang, C. H., Hsu, C. H., & Shao, Y. Y. (2025). Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 12, 2341-2349. https://doi.org/10.2147/jhc.s548785
Vancouver
Chen CT, Chuang CH, Hsu CH, Shao YY. Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2025;Volume 12:2341-2349. doi:10.2147/jhc.s548785
BibTeX
@article{Chen2025,
author = {Chen, Ching-Tso and Chuang, Chien-Huai and Hsu, Chih-Hung and Shao, Yu-Yun},
title = {Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma},
journal = {Journal of Hepatocellular Carcinoma},
year = {2025},
volume = {Volume 12},
pages = {2341--2349},
doi = {10.2147/jhc.s548785}
}
EUVIMED